Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spectrum 3: Omidenepag Isopropyl vs Timolol in Glaucoma and Ocular Hypertension
NCT03691649Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omidenepag isopropyl in Glaucoma and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Intraocular Pressure at 3 months. Started Sep 2018; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT03691649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691649.